Compare Logitech International SA (LOGI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Merck & Co., Inc. — how do they compare? Logitech International SA trades at $103.79 (market cap $14.96B), while Merck & Co., Inc. trades at $133.06 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 21.5× Logitech International SA's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| LOGI | MRK | |
|---|---|---|
Market Cap | $14.96B | $321.77B |
Sector | Technology | Health |
52-Week High | $126.69 | $131.84 |
52-Week Low | $85.84 | $77.60 |
Enterprise Value | $13.30B | $368.53B |
Dividend Yield | 1.64% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $103.28, down 1.52% on the day, with a bearish technical signal and mixed analyst sentiment. Recent Q1 2027 earnings beat expectations with EPS of $1.85 versus $1.26 expected, driven by tariff refunds and premium demand. However, a semiconductor supplier shutdown poses near-term supply chain risks. The stock shows strong profitability with a net margin of 16.28% and ROE of 35.29%, but valuation multiples like P/E of 19.03 and P/S of 3.1 suggest moderate pricing.
Outlook is cautious due to supply constraints overshadowing solid fundamentals. The consensus price target is $109.75, offering ~6% upside, but investor sentiment is divided with equal buy and sell ratings. Key risks include execution on supply chain mitigation and competitive pressures in the gaming and peripherals market. Near-term performance hinges on resolving supplier issues to meet robust demand.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
